{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T19:34:49Z","timestamp":1791488089254,"version":"4.3.4"},"reference-count":45,"publisher":"The Endocrine Society","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Sodium-glucose cotransporter-2 (SGLT2) inhibitors are effective medications for type 2 diabetes (T2D), chronic kidney disease, and chronic heart failure regardless of diabetic status. However, concerns remain about their potential to reduce skeletal muscle mass. This study clearly demonstrates that tofogliflozin (Tofo), an SGLT2 inhibitor, improves skeletal muscle mitochondrial function, morphology, and performance in a mouse model of T2D with dexamethasone (Dex)-induced muscle atrophy. Obese diabetic KK-Ay mice and nondiabetic KK mice were used. Muscle atrophy was induced in the KK-Ay mice by intraperitoneal Dex injections for 2 weeks, followed by Tofo administration (0.015%) in the diet for 2 weeks. Tofo treatment enhanced exercise endurance, restored mitochondrial morphology, increased succinate dehydrogenase activity, and elevated protein expression of optic atrophy 1 and dynamin-related protein 1. These changes were associated with AMPK (adenosine monophosphate\u2013activated protein kinase) activation and reduced expression of the mitokine growth differentiation factor-15. Although Tofo increased muscle cross-sectional area, it did not significantly affect overall body or muscle mass, nor grip strength, suggesting a preferential effect on slow-twitch oxidative fibers. Importantly, these benefits occurred without weight loss, likely due to maintained or increased food intake. These findings suggest that Tofo specifically ameliorates mitochondrial dysfunction and improves muscle quality and endurance in diabetic sarcopenia, especially under preserved nutritional conditions. Because Tofo is a highly selective SGLT2 inhibitor with distinct pharmacokinetic properties, these results are specific to Tofo and should not be generalized to all SGLT2 inhibitors. Further studies are warranted to determine whether similar effects are observed with other agents in this class.<\/jats:p>","DOI":"10.1210\/jendso\/bvaf171","type":"journal-article","created":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T13:11:32Z","timestamp":1761916292000},"source":"Crossref","is-referenced-by-count":4,"title":["Effect of Tofogliflozin on Skeletal Muscle Mitochondrial Function in Male Diabetic Mice With Muscle Atrophy"],"prefix":"10.1210","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7925-5133","authenticated-orcid":false,"given":"Chiaki","family":"Kishida","sequence":"first","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7920-269X","authenticated-orcid":false,"given":"Maki","family":"Murakoshi","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0069-5553","authenticated-orcid":false,"given":"Hiroko","family":"Sakuma","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4788-4543","authenticated-orcid":false,"given":"Terumi","family":"Shibata","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4077-9747","authenticated-orcid":false,"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0513-4433","authenticated-orcid":false,"given":"Tomohito","family":"Gohda","sequence":"additional","affiliation":[{"name":"Department of Nephrology, Juntendo University Faculty of Medicine , Bunkyo-ku, Tokyo 113-8421 ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"12","key":"2026012902463142200_bvaf171-B1","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1007\/s00198-015-3194-y","article-title":"Comparative performance of current definitions of sarcopenia against the prospective incidence of falls among community-dwelling seniors age 65 and older","volume":"26","author":"Bischoff-Ferrari","year":"2015","journal-title":"Osteoporos Int"},{"issue":"1","key":"2026012902463142200_bvaf171-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/jcsm.12048","article-title":"SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes","volume":"7","author":"Malmstrom","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"2026012902463142200_bvaf171-B3","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1093\/gerona\/glx245","article-title":"Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the longitudinal aging study Amsterdam. The journals of gerontology series A","volume":"73","author":"Schaap","year":"2018","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"2026012902463142200_bvaf171-B4","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.2147\/DMSO.S186600","article-title":"Sarcopenia and type 2 diabetes mellitus: a bidirectional relationship","volume":"12","author":"Mesinovic","year":"2019","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"1","key":"2026012902463142200_bvaf171-B5","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s40265-014-0337-y","article-title":"Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus","volume":"75","author":"Scheen","year":"2015","journal-title":"Drugs"},{"issue":"21","key":"2026012902463142200_bvaf171-B6","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"N Engl J Med"},{"issue":"22","key":"2026012902463142200_bvaf171-B7","doi-asserted-by":"crossref","first-page":"13749","DOI":"10.3390\/ijms232213749","article-title":"Sodium-glucose cotransporter-2 inhibitors-miracle drugs for the treatment of chronic kidney disease irrespective of the diabetes Status: lessons from the dedicated kidney disease-focused CREDENCE and DAPA-CKD trials","volume":"23","author":"Gohda","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2026012902463142200_bvaf171-B8","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s40265-019-1057-0","article-title":"Emerging role of SGLT-2 inhibitors for the treatment of obesity","volume":"79","author":"Pereira","year":"2019","journal-title":"Drugs"},{"issue":"6","key":"2026012902463142200_bvaf171-B9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1517\/14740338.2015.1034105","article-title":"Short-term impacts of sodium\/glucose co-transporter 2 inhibitors in Japanese clinical practice: considerations for their appropriate use to avoid serious adverse events","volume":"14","author":"Yabe","year":"2015","journal-title":"Expert Opin Drug Saf"},{"issue":"3","key":"2026012902463142200_bvaf171-B10","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/jdi.13137","article-title":"Sodium-glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: a case report","volume":"11","author":"Yasuda","year":"2020","journal-title":"J Diabetes Investig"},{"issue":"2","key":"2026012902463142200_bvaf171-B11","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/dom.12189","article-title":"Dapagliflozin maintains glycaemic control while reducing weight and body fat mass over 2 years in patients with type 2 diabetes mellitus inadequately controlled on metformin","volume":"16","author":"Bolinder","year":"2014","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2026012902463142200_bvaf171-B12","doi-asserted-by":"crossref","first-page":"467","DOI":"10.5551\/jat.40873","article-title":"Dapagliflozin reduces fat mass without affecting muscle mass in type 2 diabetes","volume":"25","author":"Sugiyama","year":"2018","journal-title":"J Atheroscler Thromb"},{"issue":"1","key":"2026012902463142200_bvaf171-B13","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1111\/jdi.12851","article-title":"Sodium-glucose cotransporter 2 inhibitor-induced changes in body composition and simultaneous changes in metabolic profile: 52-week prospective LIGHT (Luseogliflozin: the Components of Weight Loss in Japanese Patients with Type 2 Diabetes Mellitus) study","volume":"10","author":"Sasaki","year":"2019","journal-title":"J Diabetes Investig"},{"issue":"12","key":"2026012902463142200_bvaf171-B14","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1111\/dom.15249","article-title":"Efficacy and safety of the sodium-glucose co-transporter-2 inhibitor empagliflozin in elderly Japanese adults (\u226565 years) with type 2 diabetes: a randomized, double-blind, placebo-controlled, 52-week clinical trial (EMPA-ELDERLY)","volume":"25","author":"Yabe","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2026012902463142200_bvaf171-B15","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2337\/diabetes.54.6.1615","article-title":"The pathobiology of diabetic complications: a unifying mechanism","volume":"54","author":"Brownlee","year":"2005","journal-title":"Diabetes"},{"issue":"5","key":"2026012902463142200_bvaf171-B16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s10571-014-0054-9","article-title":"Ciliary neurotrophic factor reverses aberrant mitochondrial bioenergetics through the JAK\/STAT pathway in cultured sensory neurons derived from streptozotocin-induced diabetic rodents","volume":"34","author":"Chowdhury","year":"2014","journal-title":"Cell Mol Neurobiol"},{"key":"2026012902463142200_bvaf171-B17","first-page":"53","article-title":"Sodium-glucose cotransporter 2 inhibitors and mitochondrial functions: state of the art","volume":"22","author":"Yaribeygi","year":"2023","journal-title":"EXCLI J"},{"key":"2026012902463142200_bvaf171-B18","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.freeradbiomed.2024.01.015","article-title":"Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists through effects on mitochondrial function and oxidative stress","volume":"213","author":"Luna-Marco","year":"2024","journal-title":"Free Radic Biol Med"},{"issue":"4","key":"2026012902463142200_bvaf171-B19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.3390\/antiox10040588","article-title":"Mitochondrial dysfunction is a common denominator linking skeletal muscle wasting due to disease, aging, and prolonged inactivity","volume":"10","author":"Hyatt","year":"2021","journal-title":"Antioxidants"},{"issue":"10","key":"2026012902463142200_bvaf171-B20","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1016\/j.biocel.2013.05.036","article-title":"Glucocorticoid-induced skeletal muscle atrophy","volume":"45","author":"Schakman","year":"2013","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2026012902463142200_bvaf171-B21","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1038\/nrd4467","article-title":"Muscle wasting in disease: molecular mechanisms and promising therapies","volume":"14","author":"Cohen","year":"2015","journal-title":"Nat Rev Drug Discov"},{"issue":"10","key":"2026012902463142200_bvaf171-B22","doi-asserted-by":"crossref","first-page":"3324","DOI":"10.2337\/db13-0604","article-title":"Novel hypothesis to explain why SGLT2 inhibitors inhibit only 30-50% of filtered glucose load in humans","volume":"62","author":"Abdul-Ghani","year":"2013","journal-title":"Diabetes"},{"issue":"2","key":"2026012902463142200_bvaf171-B23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/jdi.13333","article-title":"Safety and effectiveness of tofogliflozin in Japanese patients with type 2 diabetes mellitus treated in real-world clinical practice: results of a 36-month post-marketing surveillance study (J-STEP\/LT)","volume":"12","author":"Utsunomiya","year":"2021","journal-title":"J Diabetes Investig"},{"key":"2026012902463142200_bvaf171-B24","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.bbamcr.2014.11.002","article-title":"Quantitative analysis of mitochondrial morphology and membrane potential in living cells using high-content imaging, machine learning, and morphological binning","volume":"2","author":"Leonard","year":"2015","journal-title":"Biochim Biophys Acta"},{"issue":"12","key":"2026012902463142200_bvaf171-B25","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1002\/2211-5463.13014","article-title":"The sodium-glucose cotransporter 2 inhibitor tofogliflozin prevents diabetic kidney disease progression in type 2 diabetic mice","volume":"10","author":"Li","year":"2020","journal-title":"FEBS Open Bio"},{"key":"2026012902463142200_bvaf171-B26","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2025.2339","article-title":"Effects of progranulin deficiency on inflammation and fibrosis in the kidneys and liver of diabetic mice fed a high-fat diet","author":"Sakuma","year":"","journal-title":"Endocrinol Metabol"},{"key":"2026012902463142200_bvaf171-B27","doi-asserted-by":"crossref","unstructured":"Kishida C, Murakoshi M, Sakuma H, Shibata T, Suzuki Y, Gohda T. 2025. Supplemental Figure 1 for \u201cEffect of tofogliflozin on skeletal muscle mitochondrial function in male diabetic mice with muscle atrophy\u201d. Figshare. 10.6084\/m9.figshare.30069394.","DOI":"10.1210\/jendso\/bvaf171"},{"issue":"4","key":"2026012902463142200_bvaf171-B28","doi-asserted-by":"crossref","first-page":"e94032","DOI":"10.1371\/journal.pone.0094032","article-title":"Noninvasive imaging of in vivo MuRF1 expression during muscle atrophy","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"issue":"2","key":"2026012902463142200_bvaf171-B29","doi-asserted-by":"crossref","first-page":"E363-71","DOI":"10.1152\/ajpendo.00487.2002","article-title":"Glucocorticoid-induced skeletal muscle atrophy is associated with upregulation of myostatin gene expression","volume":"285","author":"Ma","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2026012902463142200_bvaf171-B30","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.2337\/db05-1183","article-title":"Decreased muscle strength and quality in older adults with type 2 diabetes: the health, aging, and body composition study","volume":"55","author":"Park","year":"2006","journal-title":"Diabetes"},{"issue":"1","key":"2026012902463142200_bvaf171-B31","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12891-020-03228-y","article-title":"Obesity-associated poor muscle quality: prevalence and association with age, sex, and body mass index","volume":"21","author":"Valenzuela","year":"2020","journal-title":"BMC Musculoskelet Disord"},{"issue":"1","key":"2026012902463142200_bvaf171-B32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1152\/physrev.00019.2003","article-title":"Cellular and molecular regulation of muscle regeneration","volume":"84","author":"Charg\u00e9","year":"2004","journal-title":"Physiol Rev"},{"issue":"1","key":"2026012902463142200_bvaf171-B33","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.stem.2016.09.010","article-title":"Myogenic progenitor cells control extracellular matrix production by fibroblasts during skeletal muscle hypertrophy","volume":"20","author":"Fry","year":"2017","journal-title":"Cell stem cell"},{"issue":"3","key":"2026012902463142200_bvaf171-B34","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1042\/BCJ20210700","article-title":"Differential effect of canagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor, on slow and fast skeletal muscles from nondiabetic mice","volume":"479","author":"Otsuka","year":"2022","journal-title":"Biochem J"},{"issue":"15","key":"2026012902463142200_bvaf171-B35","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026012902463142200_bvaf171-B36","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1007\/s00125-020-05335-w","article-title":"Human skeletal muscle mitochondrial dynamics in relation to oxidative capacity and insulin sensitivity","volume":"64","author":"Houzelle","year":"2021","journal-title":"Diabetologia"},{"issue":"8","key":"2026012902463142200_bvaf171-B37","first-page":"1499","article-title":"Melatonin improves skeletal muscle structure and oxidative phenotype by regulating mitochondrial dynamics and autophagy in z\u00fccker diabetic fatty rat","volume":"12","author":"Salagre","year":"2023","journal-title":"Antioxidants (Basel, Switzerland)"},{"issue":"6","key":"2026012902463142200_bvaf171-B38","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cmet.2017.04.021","article-title":"Age-associated loss of OPA1 in muscle impacts muscle mass, metabolic homeostasis, systemic inflammation, and epithelial senescence","volume":"25","author":"Tezze","year":"2017","journal-title":"Cell Metab"},{"issue":"3","key":"2026012902463142200_bvaf171-B39","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.cmet.2016.02.017","article-title":"AMPK promotes autophagy by facilitating mitochondrial fission","volume":"23","author":"Zhang","year":"2016","journal-title":"Cell Metab"},{"issue":"6","key":"2026012902463142200_bvaf171-B40","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/jcsm.13350","article-title":"Improved endurance capacity of diabetic mice during SGLT2 inhibition: role of AICARP, an AMPK activator in the soleus","volume":"14","author":"Nakamura","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"2026012902463142200_bvaf171-B41","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s10522-024-10093-y","article-title":"The SGLT2 inhibitor empagliflozin inhibits skeletal muscle fibrosis in naturally aging male mice through the AMPK\u03b1\/MMP9\/TGF-\u03b21\/smad pathway","volume":"25","author":"Huang","year":"2024","journal-title":"Biogerontology"},{"key":"2026012902463142200_bvaf171-B42","doi-asserted-by":"crossref","first-page":"1203666","DOI":"10.3389\/fendo.2023.1203666","article-title":"Effect of sodium-glucose transporter 2 inhibitors on sarcopenia in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2026012902463142200_bvaf171-B43","doi-asserted-by":"crossref","first-page":"1220516","DOI":"10.3389\/fendo.2023.1220516","article-title":"Relationship between sodium-glucose cotransporter-2 inhibitors and muscle atrophy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis","volume":"14","author":"Xia","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"2026012902463142200_bvaf171-B44","doi-asserted-by":"crossref","first-page":"e0279889","DOI":"10.1371\/journal.pone.0279889","article-title":"Effect of SGLT-2 inhibitors on body composition in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials","volume":"17","author":"Pan","year":"2022","journal-title":"PLoS One"},{"issue":"1","key":"2026012902463142200_bvaf171-B45","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3390\/nu16010063","article-title":"Sarcopenia and diabetes: a detrimental liaison of advancing age","volume":"16","author":"Lisco","year":"2023","journal-title":"Nutrients"}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvaf171\/65107592\/bvaf171.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf171\/65107592\/bvaf171.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jes\/article-pdf\/10\/2\/bvaf171\/65107592\/bvaf171.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T07:46:44Z","timestamp":1769672804000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvaf171\/8313060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,1,7]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvaf171","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,2]]},"published":{"date-parts":[[2025,11,3]]},"article-number":"bvaf171"}}